| BioHelix announced today that it was awarded
three Small Business Innovative Research (SBIR) grants from the National
Institutes of Health. Two phase I SBIR grants for the development
of diagnostic assays based on BioHelix "instrument-free"
IsoAmp platform. One supports the development of IsoAmp Group B Strep
assay for detecting colonization by Streptococcus agalactiae in pregnant
women and one supports the development of low-cost IsoAmp HIV assay.
In addition, the company also receives a 3-year phase 2 award for
developing Herpes virus typing assay for detecting genital herpes
based on an isothermal realtime detection platform. The SBIR awards
will enable BioHelix to continue developing innovative isothermal
amplification technologies for use in clinical diagnostics. |
